147 related articles for article (PubMed ID: 16952134)
1. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
Jurk M; Kritzler A; Debelak H; Vollmer J; Krieg AM; Uhlmann E
ChemMedChem; 2006 Sep; 1(9):1007-14. PubMed ID: 16952134
[TBL] [Abstract][Full Text] [Related]
2. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
3. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
4. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
7. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
Putta MR; Yu D; Bhagat L; Wang D; Zhu FG; Kandimalla ER
J Med Chem; 2010 May; 53(9):3730-8. PubMed ID: 20361743
[TBL] [Abstract][Full Text] [Related]
8. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
Yu D; Wang D; Zhu FG; Bhagat L; Dai M; Kandimalla ER; Agrawal S
J Med Chem; 2009 Aug; 52(16):5108-14. PubMed ID: 19650625
[TBL] [Abstract][Full Text] [Related]
9. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
10. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
11. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
13. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
14. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.
Bauer S; Kirschning CJ; Häcker H; Redecke V; Hausmann S; Akira S; Wagner H; Lipford GB
Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9237-42. PubMed ID: 11470918
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory CpG oligonucleotides form defined three-dimensional structures: results from an NMR study.
He G; Patra A; Siegmund K; Peter M; Heeg K; Dalpke A; Richert C
ChemMedChem; 2007 Apr; 2(4):549-60. PubMed ID: 17366653
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
17. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides.
Brownlie R; Zhu J; Allan B; Mutwiri GK; Babiuk LA; Potter A; Griebel P
Mol Immunol; 2009 Sep; 46(15):3163-70. PubMed ID: 19573927
[TBL] [Abstract][Full Text] [Related]
18. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation.
Haas T; Metzger J; Schmitz F; Heit A; Müller T; Latz E; Wagner H
Immunity; 2008 Mar; 28(3):315-23. PubMed ID: 18342006
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]